Nemocnica Na Okraji Mesta N.O.
- Address
- lock Available on a paid plan
Neoplasms
The oncology department at Nemocnica Na Okraji Mesta N.O. is actively evaluating new treatment options for a range of solid tumours, including non‑small cell lung cancer, melanoma with BRAF V600E/K mutations, and hormone‑responsive breast cancers. Researchers are comparing innovative immunotherapy combinations with standard chemotherapy to determine if they can improve response rates and survival outcomes.
- Comparative studies of novel checkpoint inhibitor biosimilars in advanced lung cancer
- Combination of targeted agents and immunotherapy for BRAF‑mutated melanoma
- Evaluation of antibody‑drug conjugates for triple‑negative breast cancer
- Assessment of hormonal therapy plus CDK4/6 inhibition in estrogen‑receptor positive breast cancer
- Investigation of first‑line immunotherapy regimens in non‑squamous lung cancer
Across eight clinical trials, six investigators are working to bring more effective therapies to patients in Partizanske, Slovakia, reflecting the site’s commitment to advancing cancer care.
Nutritional and Metabolic Diseases
In addition to tumour‑directed studies, the centre is dedicated to addressing metabolic complications such as cancer cachexia that often accompany advanced disease. Trials focus on agents that may restore body weight and improve quality of life for patients with colorectal cancer and other malignancies experiencing severe weight loss.
- Anti‑GDF‑15 antibody therapy to increase body weight in cachectic cancer patients
- Oral metabolic modulators aimed at improving appetite in colorectal cancer with cachexia
- Safety and efficacy evaluation of novel agents targeting muscle wasting pathways
- Placebo‑controlled studies measuring weight change and functional outcomes
- Exploratory biomarkers of metabolic health in patients with advanced tumours
These eight trials, supported by a multidisciplinary team, highlight the site’s integrated approach to treating both the tumour and its systemic effects, offering hope for better overall patient wellbeing.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Mabxience Research S.L.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnica Na Okraji Mesta N.O.
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| C4891001 - A Phase 3, Randomized, Open-Label, Multicenter Trial Of Arv-471 (PF-07850327) vs Fulvestrant In participants With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment For Advanced Disease (VERITAC-2) | Pfizer Inc. | Phase III | Not Recruiting | Jun 2023 | — |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione | 2 | Unknown | 2023-06-05 | 2023-10-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.